Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am in at GCM.TO too. Gran Colombia Gold corp .
Article:China,not the Brexit is the biggest problem of the world.
http://www.investopedia.com/articles/markets/072916/china-not-brexit-biggest-problem-world.asp?partner=YahooSA&yptr=yahoo
I agree.Europe growth is bad,US growth is bad. Fed will continue quantitative easing, more central banks will start to introduce negative rates, Brexit, maybe other countries leaving the EU. All good for gold.
Gold should continue to rise and that will make your target a realistic target for the medium term (2 years).
How high do you think it can go?
Titanium+gold=new gold standard for artifical joints
Rice lab discovers titanium-gold alloy that is four times harder than most steels
Titanium is the leading material for artificial knee and hip joints because it’s strong, wear-resistant and nontoxic, but an unexpected discovery by Rice University physicists shows that the gold standard for artificial joints can be improved with the addition of some actual gold.
“It is about 3-4 times harder than most steels,” said Emilia Morosan, the lead scientist on a new study in Science Advances that describes the properties of a 3-to-1 mixture of titanium and gold with a specific atomic structure that imparts hardness. “It’s four times harder than pure titanium, which is what’s currently being used in most dental implants and replacement joints.”
Morosan, a physicist who specializes in the design and synthesis of compounds with exotic electronic and magnetic properties, said the new study is “a first for me in a number of ways. This compound is not difficult to make, and it’s not a new material.”
In fact, the atomic structure of the material — its atoms are tightly packed in a “cubic” crystalline structure that’s often associated with hardness — was previously known. It’s not even clear that Morosan and former graduate student Eteri Svanidze, the study’s lead co-author, were the first to make a pure sample of the ultrahard “beta” form of the compound. But due to a couple of lucky breaks, they and their co-authors are the first to document the material’s remarkable properties.
This began from my core research,” said Morosan, professor of physics and astronomy, of chemistry and of materials science and nanoengineering at Rice. “We published a study not long ago on titanium-gold, a 1-to-1 ratio compound that was a magnetic material made from nonmagnetic elements. One of the things that we do when we make a new compound is try to grind it into powder for X-ray purposes. This helps with identifying the composition, the purity, the crystal structure and other structural properties.
“When we tried to grind up titanium-gold, we couldn’t,” she recalled. “I even bought a diamond (coated) mortar and pestle, and we still couldn’t grind it up.”
Morosan and Svanidze decided to do follow-up tests to determine exactly how hard the compound was, and while they were at it, they also decided to measure the hardness of the other compositions of titanium and gold that they had used as comparisons in the original study.
Eteri Svanidze and Emilia Morosan
Eteri Svanidze (left) and Emilia Morosan (Photo by Jeff Fitlow/Rice University)
One of the extra compounds was a mixture of three parts titanium and one part gold that had been prepared at high temperature.
What the team didn’t know at the time was that making titanium-3-gold at relatively high temperature produces an almost pure crystalline form of the beta version of the alloy — the crystal structure that’s four times harder than titanium. At lower temperatures, the atoms tend to arrange in another cubic structure — the alpha form of titanium-3-gold. The alpha structure is about as hard as regular titanium. It appears that labs that had previously measured the hardness of titanium-3-gold had measured samples that largely consisted of the alpha arrangement of atoms.
The team measured the hardness of the beta form of the crystal in conjunction with colleagues at Texas A&M University’s Turbomachinery Laboratory and at the National High Magnetic Field Laboratory at Florida State University, Morosan and Svanidze also performed other comparisons with titanium. For biomedical implants, for example, two key measures are biocompatibility and wear resistance. Because titanium and gold by themselves are among the most biocompatible metals and are often used in medical implants, the team believed titanium-3-gold would be comparable. In fact, tests by colleagues at the University of Texas MD Anderson Cancer Center in Houston determined that the new alloy was even more biocompatible than pure titanium. The story proved much the same for wear resistance: Titanium-3-gold also outperformed pure titanium.
Morosan said she has no plans to become a materials scientist or dramatically alter her lab’s focus, but she said her group is planning to conduct follow-up tests to further investigate the crystal structure of beta titanium-3-gold and to see if chemical dopants might improve its hardness even further.
Additional co-authors include Pulickel Ajayan, Sruthi Radhakrishnan and Chandra Sekhar Tiwary, all of Rice; Tiglet Besara, Yan Xin, Ke Han and Theo Siegrist, all of Florida State; Fevzi Ozaydin and Hong Liang, both of Texas A&M; and Sendurai Mani of MD Anderson. The research was supported by the National Science Foundation, the Department of Energy, Texas A&M’s Turbomachinery Laboratory and the Florida State University Research Foundation.
- See more at: http://news.rice.edu/2016/07/20/titanium-gold-new-gold-standard-for-artificial-joints/#sthash.8hi6vkju.dpuf
Time to buy stocks instead of gold. IMO gold will head back to $800 + extra royalties for gold miners to pay the government means good news for DUST. Again: In my opinion of course
Gold Miners Face Potential Crisis as World Governments Boost Royalties
http://oilnewsfeed.com/2016/07/20/gold-miners-face-potential-crisis-as-world-governments-boost-royalties/
Gold Miners Face Potential Crisis as World Governments Boost Royalties
http://oilnewsfeed.com/2016/07/20/gold-miners-face-potential-crisis-as-world-governments-boost-royalties/
$10 is just the start.More like $300-400 because gold is done for the next 7years. End of the gold cycle.
Gold will creep back to its' cave of $800. Only idiots want to buy gold above $800. Economy is doing great. Dust is going to $300-400/share and fund managers are starting to realize it as well.
Gold is going back to its' cave of $800. The economy is doing great and only an idiot wants to buy gold above $800.
I am from Europe and trust me, people from Europe do NOT want Turkey to join the EU. We have never wanted that.
Now it is my turn to wish you good luck
You see ghosts.I only see a gold price which is too expensive and which will come back to $800.
It will bring it to $5-7/share and a reverse split 1:10. But more importantly it will bring DUST to $300-400/share
Asia is getting stronger, European stock markets are doing great and DOW and Nasdaq are at record highs. Everybody goes into stocks and short in gold. Shorting gold and buying DUST is a one in a lifetime gift to get rich.
Crisis is over. Central banks will regain intrest at $800. Learn it the hard way if you want. Fund will now make money on the short side of gold.
Only an idiot buys gold at this price. Gold will be heading back to its' cave, back to $800
Hedge Funds Finally Say No to Gold as U.S. Shares Smoke Records
http://www.bloomberg.com/news/articles/2016-07-17/hedge-funds-finally-say-no-to-gold-as-u-s-shares-smoke-records?cmpid=yhoo.headline&yptr=yahoo
Hedge Funds Finally Say No to Gold as U.S. Shares Smoke Records
http://www.bloomberg.com/news/articles/2016-07-17/hedge-funds-finally-say-no-to-gold-as-u-s-shares-smoke-records?cmpid=yhoo.headline&yptr=yahoo
The situation in Turkey is back under controll. The military coup has failed. This Geens like a bull trap on gold. Gold is going to be destroyed on Monday. DUST will be over $8-10 next week.
The situation in Turkey is back under controll. The military coup has failed. This Geens like a bull trap on gold. Gold is going to be destroyed on Monday
I agree. I have bought it on the Toronto Exchange. 10,000 shares, small position, very long time position
AEZS:$12/share target reaffirmed+institutional buying
stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Sunday.
Shares of Aeterna Zentaris (NASDAQ:AEZS) traded up 2.42% during midday trading on Friday, reaching $3.38. 107,781 shares of the company traded hands. Aeterna Zentaris has a 1-year low of $2.60 and a 1-year high of $25.00. The company’s market capitalization is $33.59 million. The company has a 50 day moving average price of $3.44 and a 200 day moving average price of $3.52.
An institutional investor recently raised its position in Aeterna Zentaris stock. Renaissance Technologies LLC boosted its stake in Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned about 8.17% of Aeterna Zentaris worth $1,716,000 as of its most recent filing with the SEC.
AEZS has been the subject of several other research reports. Maxim Group reaffirmed a “buy” rating and issued a $11.00 price target on shares of Aeterna Zentaris in a research report on Tuesday, May 10th. Canaccord Genuity reaffirmed a “buy” rating and issued a $9.00 price target (down previously from $13.00) on shares of Aeterna Zentaris in a research report on Monday, April 4th.
http://www.americanbankingnews.com/2016/07/11/aeterna-zentaris-aezs-buy-rating-reaffirmed-at-hc-wainwright/
http://www.smarteranalyst.com/2016/07/11/h-c-wainwright-pounds-table-aeterna-zentaris-inc-usa/
AEZS:$12/share target reaffirmed+institutional buying
stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Sunday.
Shares of Aeterna Zentaris (NASDAQ:AEZS) traded up 2.42% during midday trading on Friday, reaching $3.38. 107,781 shares of the company traded hands. Aeterna Zentaris has a 1-year low of $2.60 and a 1-year high of $25.00. The company’s market capitalization is $33.59 million. The company has a 50 day moving average price of $3.44 and a 200 day moving average price of $3.52.
An institutional investor recently raised its position in Aeterna Zentaris stock. Renaissance Technologies LLC boosted its stake in Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned about 8.17% of Aeterna Zentaris worth $1,716,000 as of its most recent filing with the SEC.
AEZS has been the subject of several other research reports. Maxim Group reaffirmed a “buy” rating and issued a $11.00 price target on shares of Aeterna Zentaris in a research report on Tuesday, May 10th. Canaccord Genuity reaffirmed a “buy” rating and issued a $9.00 price target (down previously from $13.00) on shares of Aeterna Zentaris in a research report on Monday, April 4th.
http://www.americanbankingnews.com/2016/07/11/aeterna-zentaris-aezs-buy-rating-reaffirmed-at-hc-wainwright/
http://www.smarteranalyst.com/2016/07/11/h-c-wainwright-pounds-table-aeterna-zentaris-inc-usa/
Thank you
GCM:Profitable when the gold price had an average of 1190 and in the know they have produced more gold quarter after quarter. THAT MAKES IT A STRONG BUY FOR ME."
GCM: agreed, GranColumbiaGoldCorp=a Strong buy and undervalued. Just bought 10,000 shares
AEZS:Strong cash position $33m as of March 31st, cash burn $2.8m/month. Two main products: (1) Zoptrex, phase 3 results available this quarter which could be the first FDA and EMA approved treatment for endometrial cancer
(2) Macrilen, phase 3 results available this quarter, to diagnose AGHD and AGHD after TBI. A much less invasive, less time consuming and less risky (no risk for hypoglycemic coma) compared to the insuline tolerance test. Two partnerships signed for Zoptrex for two of the most difficult-though very large and commercially very attractive - regions in the world: China + SouthEast Asia.
Two succesfully phase 2 results for Zoptrex for ovarian and prostate cancer, ready to go into phase 3.
Potential revenues for Zoptrex for endometrial cancer in the US alone: $300million/annually
Potential revenues for Macrilen (including AGHD caused by TBI) in the US alone: upto $200million/annually
US sales force is already available b/c the company is already selling products for endocrinology, oncology and womens' health on a commission basis.
AEZS:Strong cash position $33m as of March 31st, cash burn $2.8m/month. Two main products: (1) Zoptrex, phase 3 results available this quarter which could be the first FDA and EMA approved treatment for endometrial cancer
(2) Macrilen, phase 3 results available this quarter, to diagnose AGHD and AGHD after TBI. A much less invasive, less time consuming and less risky (no risk for hypoglycemic coma) compared to the insuline tolerance test. Two partnerships signed for Zoptrex for two of the most difficult-though very large and commercially very attractive - regions in the world: China + SouthEast Asia.
Two succesfully phase 2 results for Zoptrex for ovarian and prostate cancer, ready to go into phase 3.
Potential revenues for Zoptrex for endometrial cancer in the US alone: $300million/annually
Potential revenues for Macrilen (including AGHD caused by TBI) in the US alone: upto $200million/annually
US sales force already available b/c the company is already selling products for endocrinology, oncology and womens' health on a commission basis.
Strong cash position $33m as of March 31st, cash burn $2.8m/month. Two main products: (1) Zoptrex, phase 3 results available this quarter which could be the first FDA and EMA approved treatment for endometrial cancer
(2) Macrilen, phase 3 results available this quarter, to diagnose AGHD and AGHD after TBI. A much less invasive, less time consuming and less risky (no risk for hypoglycemic coma) compared to the insuline tolerance test. Two partnerships signed for Zoptrex for two of the most difficult-though very large and commercially very attractive - regions in the world: China + SouthEast Asia.
Two succesfully phase 2 results for Zoptrex for ovarian and prostate cancer, ready to go into phase 3.
Potential revenues for Zoptrex for endometrial cancer in the US alone: $300million/annually
Potential revenues for Macrilen (including AGHD caused by TBI) in the US alone: upto $200million/annually
US sales force already available b/c the company is already selling products for endocrinology, oncology and womens' health on a commission basis.
This is the most UNDERVALUED stock of the entire Nasdaq!
Another partnership for Zoptrex,now for Taiwan and Southasia!!
Aeterna Zentaris Inc. (AEZS) (AEZ.TO) (the “Company”) and Orient EuroPharma Co., Ltd. (“OEP”) today announced the signing of an exclusive license agreement between the Company and Cyntec Co., Ltd., an affiliate of OEP (“Cyntec”), for the Company’s lead anti-cancer compound, Zoptrex™ (zoptarelin doxorubicin), for the initial indication of endometrial cancer, for Taiwan and nine countries in Southeast Asia (the “Territory”). Zoptrex™, a novel synthetic peptide carrier linked to doxorubicin as a New Chemical Entity (NCE), is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer. The Company expects to complete the Phase 3 clinical trial in the third quarter of 2016 and, if the results of the trial warrant doing so, to file a new drug application for Zoptrex™ in the first half of 2017.
http://finance.yahoo.com/news/aeterna-zentaris-orient-europharma-co-123000314.html
XTNT: New$$$:Xtant Medical and Pinnacle Spine Group Announce Distribution Agreement, Expanding the Availability of Innovative InFill® Lateral Fusion System
BELGRADE, Mont. and DALLAS, June 08, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices and Pinnacle Spine Group, LLC, a developer of innovative spinal fusion solutions, today announced a joint agreement to expand distribution of Pinnacle's InFill® Lateral Lumbar Interbody Fusion System. Through this agreement, Xtant enters the lateral lumbar interbody fusion market, expanding its spinal hardware portfolio.
The foundation of Pinnacle Spine Group's complete InFill fusion systems is its patented ability to deliver bone graft material to the fusion device in situ. The unique features of the InFill Lateral Fusion device combined with the InFill Graft Delivery System provide the opportunity for a more robust fusion column and maximized bone graft-to-endplate contact. The InFill Lateral Lumbar Interbody Fusion system is intended for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1.
"We are excited to partner with Xtant Medical, a recognized industry leader, to bring new and innovative solutions to spine surgeons," said Zach Sowell, President of Pinnacle Spine Group. "Our patented innovative technology offers a terrific platform for Xtant and Pinnacle to grow their core competencies and expand their scope in the spinal fusion segment."
"It is a very exciting time for Xtant Medical as we continue to broaden our portfolio. This system will allow Xtant Medical to meet the needs of orthopedic and neuro spine surgeons who currently practice minimally invasive spine surgery or looking to expand their procedural options," stated Dr. David Kirschman, Executive Vice President and Chief Scientific Officer.
According to iData Research, it is estimated that the US market for lateral lumber interbody fusion in 2015 was nearly $254M and is expected to be close to $309M in 2020.
http://finance.yahoo.com/news/xtant-medical-pinnacle-spine-group-105900035.html
New$$$:Xtant Medical and Pinnacle Spine Group Announce Distribution Agreement, Expanding the Availability of Innovative InFill® Lateral Fusion System
BELGRADE, Mont. and DALLAS, June 08, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices and Pinnacle Spine Group, LLC, a developer of innovative spinal fusion solutions, today announced a joint agreement to expand distribution of Pinnacle's InFill® Lateral Lumbar Interbody Fusion System. Through this agreement, Xtant enters the lateral lumbar interbody fusion market, expanding its spinal hardware portfolio.
The foundation of Pinnacle Spine Group's complete InFill fusion systems is its patented ability to deliver bone graft material to the fusion device in situ. The unique features of the InFill Lateral Fusion device combined with the InFill Graft Delivery System provide the opportunity for a more robust fusion column and maximized bone graft-to-endplate contact. The InFill Lateral Lumbar Interbody Fusion system is intended for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1.
"We are excited to partner with Xtant Medical, a recognized industry leader, to bring new and innovative solutions to spine surgeons," said Zach Sowell, President of Pinnacle Spine Group. "Our patented innovative technology offers a terrific platform for Xtant and Pinnacle to grow their core competencies and expand their scope in the spinal fusion segment."
"It is a very exciting time for Xtant Medical as we continue to broaden our portfolio. This system will allow Xtant Medical to meet the needs of orthopedic and neuro spine surgeons who currently practice minimally invasive spine surgery or looking to expand their procedural options," stated Dr. David Kirschman, Executive Vice President and Chief Scientific Officer.
According to iData Research, it is estimated that the US market for lateral lumber interbody fusion in 2015 was nearly $254M and is expected to be close to $309M in 2020.
http://finance.yahoo.com/news/xtant-medical-pinnacle-spine-group-105900035.html
XTNT:This is the only medical device stock worth having.Awesome potential: low float (12.5M shares outstanding),NYSE listed,1y target $8/share,will become breakeven this year,great pipeline. Current pps is $2.20/share.
XTNT:the only medical device stock worth having.Awesome potential: low float (12.5M shares outstanding),NYSE listed,1y target $8/share,will become breakeven this year,great pipeline. Current pps is $2.20/share.
Great potential here.
Absolutely. Three products they sell and two products in phase 3.
Yes, I agree.